“Our solitary dose treatment design allows a short treatment period which positions BPL-003 like a likely interesting and scalable treatment possibility,” claimed Mellen. “Less than fifteen% of clients with treatment resistant depression obtain lengthy-term remission with the current regular of care, and we anticipate even further validating